The pathophysiology of NAFL and NASH is complex and numerous intermediaries are
involved. Each year brings new and exciting developments as pieces of the …

Chronic liver diseases often result in the development of liver fibrosis and ultimately,
cirrhosis. Treatment strategies and prognosis differ greatly depending on the severity of liver …

Tissue stiffness has long been known to be a biomarker of tissue pathology. Ultrasound
elastography measures tissue mechanical properties by monitoring the response of tissue to …

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of abnormal liver tests
in industrial countries. It encompasses the spectrum of liver damage from simple steatosis to …

Background The value of transient elastography for the non-invasive diagnosis of alcohol-
related liver fibrosis is subject to debate. We did an individual patient data (IPD) meta …

Transjugular intrahepatic portosystemic shunt (TIPS) efficiently treats complications of portal
hypertension. Liver and spleen stiffness might predict clinically significant portal …

Hepatocellular carcinoma (HCC) is an aggressive tumor with limited systemic and
locoregional modalities of treatment. Although microRNA (miRNA) based therapies have …

Little information is available on the impact of direct‐acting antiviral (DAA) therapy on
changes in liver fibrosis and steatosis. Liver stiffness (LS) and controlled attenuation …

Nonalcoholic fatty liver disease is a type of hepatic steatosis that is not only associated with
critical metabolic risk factors but can also result in advanced liver diseases. Ultrasound …

Aim Whether direct-acting antiviral (DAA) therapy can reduce liver fibrosis and steatosis in
patients with chronic hepatitis C virus (HCV) infection remains unclear. We evaluated …